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Abstract
Objectives: The National Health Service Bowel Cancer Screening Programme (NHS BCSP) in England has replaced guaiac
faecal occult blood testing by faecal immunochemical testing (FIT). There is interest in fully exploiting FIT measures to improve
bowel cancer (CRC) screening strategies. In this paper, we estimate the relationship of the quantitative haemoglobin concen-
tration provided by FIT in faecal samples with underlying pathology. From this we estimate thresholds required for given levels
of sensitivity to CRC and high-risk adenomas (HRA).
Methods: Data were collected from a pilot study of FIT in England in 2014, in which 27,238 participants completed a FIT.
Those with a faecal haemoglobin concentration (f-Hb) of at least 20 mg/g were referred for further investigation, usually
colonoscopy. Truncated regression models were used to explore the relationship between bowel pathology and FIT results.
Regression results were applied to estimate sensitivity to different abnormalities for a number of thresholds.
Results: Participants with CRC and HRA had significantly higher f-Hb, and this remained unchanged after adjusting for age and
sex. While a threshold of 20 lg/g was estimated to capture 82.2% of CRC and 64.0% of HRA, this would refer 7.8% of
participants for colonoscopy. The current programme threshold used in England of 120 lg/g was estimated to identify 47.8% of
CRC and 25.0% of HRA.
Conclusions: Under the current diagnostic policy of dichotomising FIT results, a very low threshold would be required to
achieve high sensitivity to CRC and HRA, which would place further strain on colonoscopy resources. The NHS BCSP in
England might benefit from a diagnostic policy that makes greater use of the quantitative nature of FIT.
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Introduction
Bowel cancer (colorectal cancer, CRC) is the second most
common cause of cancer death in the UK, accounting for
10% of all cancer deaths in 2017.1 Between 2015 and 2017,
there were around 16,300 CRC deaths in the UK every
year, equivalent to 45 deaths every day.1 In order to
reduce mortality and incidence of CRC, the National
Health Service Bowel Cancer Screening Programme
(NHS BCSP) in England offers tests for the presence of
occult blood in faeces free of charge every two years for
men and women aged 60–74 years (inclusive).
Up to 7 June 2019, the guaiac faecal occult blood test
(gFOBT) was the method used and this gives a binary
result (positive or negative) for each sample.2,3 It requires
two faecal samples from each of three separate bowel
motions to attain satisfactory sensitivity. In contrast, the
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faecal immunochemical test (FIT) gives a quantitative
result in the form of micrograms of haemoglobin per
gram of faeces (lg/g), and requires only a single sample.
In 2014 the NHS BCSP in England performed a pilot
study to examine the acceptability and diagnostic perfor-
mance of FIT in two of the five regional hubs managing
the established screening programme in England.
The main analysis of the FIT pilot study by Moss et al.3
assessed the effect of varying faecal haemoglobin concen-
tration (f-Hb) threshold on detection rate of CRC and
advanced adenomas (high-risk and intermediate-risk ade-
nomas combined, as defined by Moss et al: see the
Pathology section for definitions), and on the colonoscopy
rate. This information was very useful for informing the
national programme, but because those with f-Hb less
than 20 lg/g did not receive further investigation, it did
not estimate the numbers of abnormalities missed for a
given threshold. Also, it did not consider the relationship
in the direction of causality: it is the abnormalities that
cause bleeding, and therefore the FIT result. This paper
aims to complement the previous results by:
1. Exploring the relationship between FIT results and
bowel pathology using truncated regression, in both a
univariate and multiple regression model, with demo-
graphic factors including age, sex and area-based socio-
economic status; and
2. Using these results to estimate proportions of bowel
abnormalities the screening programme would fail to
diagnose at different FIT thresholds (false negative
rates);
3. Generating hypotheses for fuller exploitation of quan-
titative FIT measures.
Methods
Bowel cancer screening programme in England
The NHS BCSP in England started to adopt FIT in June
2019.2 Currently, the policy is to have a single threshold
indicating further diagnostic workup for those at or above
the threshold, or return to routine screening for those
below. The diagnostic performance of FIT for detecting
CRC and adenomas depends on the threshold defined for
positivity. The programme uses a threshold of 120 lg/g for
referral for further investigation (Figure 1).
Study population
The 2014 FIT pilot study drew samples from the routine
screening population invited by two of the five English
BCSP Hubs (the Midlands and North West Hub and the
Southern Hub). The study protocol pseudo-randomly
assigned every 28th consecutive invitee to receive a FIT
instead of a gFOBT kit.3 Those who were offered FIT
will be referred to as invitees below, and those who gave
valid FIT results will be referred to as participants. There
were 40,928 invitees aged 59–75 (inclusive) years old, and
27,238 participants (14,404 women and 12,834 men). Only
those 2133 participants with a positive f-Hb, defined as at
least 20 lg/g, were invited for further investigation (usually
colonoscopy). At the end of the pilot study, 1825 partic-
ipants had a definitive pathology outcome. These are
referred to as complete cases below.
The dataset used in this paper was extracted from BCSS
(Bowel Cancer Screening System) with reference
ODR_1819_103. It has been substantially updated and
cleaned since the previous publication, in particular
including FIT results which became available after the pre-
vious publication was written, and so will not have exactly
the same numbers as previously reported.3–5 Compared to
the previous paper, we therefore report on two fewer invit-
ees (40,928 vs. 40,930), 71 more participants with valid
FIT results (27,238 vs. 27,167), six more positive tests
(2133 vs. 2127) and one more colonoscopy result (1825
vs. 1824).
Pathology
After a colonoscopy, pathologists examined removed tis-
sues (if any) and classified those according to the recom-
mendations from The British Society of Gastroenterology
(BSG).6 In this paper, we re-categorised pathology out-
comes defined as follows:
1. Low-risk adenomas (LRA), if removed tissues con-
tained 1–2 adenomas and were both small (less than 1
cm in diameter);
2. Intermediate-risk adenomas (IRA), if removed tissues
contained 3–4 small adenomas or 1–2 adenomas of
which at least one has diameter greater than or equal
to 1 cm;
3. High-risk adenomas (HRA), if removed tissues con-
tained at least five small adenomas or three or more
adenomas at least one of which is greater or equal to
1 cm in diameter;
4. Cancer (CRC) if removed tissues had characteristic of
malignancy;
5. Other abnormality, to include all other unclassified
abnormalities; and
6. No abnormality, if removed tissues contained no
abnormalities.
Statistical analysis
In order to estimate the potential impact of deprivation on
FIT results, we used the Index of Multiple Deprivation
(IMD), which is the official and the most widely used mea-
sure of deprivation in England.7
FIT results less than 4 lg/g were recoded to 1 lg/g
(rather than zero due to the natural logarithm transforma-
tion later) and are referred to as undetectable f-Hb.8 The
limit of detection is 4lg/g; that is FIT analysers (OC-
Sensor DIANA, Eiken Chemical Co., Ltd, Japan)
cannot distinguish samples with f-Hb lower than this
from samples with no f-Hb.
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We carried out univariable and multivariable regression
analyses with the quantitative FIT measure (f-Hb) as the
dependent and pathology outcomes as independent varia-
bles. We compared proportions of participants with unde-
tectable f-Hb in their samples among demographic and
screening episode characteristics using logistic regression.
We used truncated regression since there were no
pathology data on participants with f-Hb less than
20 lg/g.9 As a result of the skewed distribution of f-Hb,
we used the natural logarithm of f-Hb as the dependent
variable. Regression coefficients were then transformed
back to the original scale to provide the ratio of geometric
mean f-Hb for each pathology, relative to no abnormality
pathology. Likelihood ratio tests were used to select the
best model, with Wald tests helping to identify significant
categories (p< 0.001) within a variable. Given previous
observed sex- and age-specific differences,3–5 the multivar-
iable model included these variables.
We also fitted truncated regression models with only
constant terms and no predictor variables, restricting anal-
ysis to each pathology category separately. These are
referred to as univariable regression models below. From
these results, we estimated the distributions of f-Hb for dif-
ferent pathology outcomes. Using these, we then estimated
the proportions of abnormalities captured by different f-Hb
thresholds, and by implication, the proportions missed for
those thresholds. We also considered the problem from the
opposite angle, calculating the thresholds required for given
levels of sensitivity to CRC and HRA.
All analyses were carried out in StataMP version 15.1
on a Windows 8 platform.
Results
Table 1 shows the demographics and screening episode of
the 40,928 invitees, and of the subpopulation of 27,238
Figure 1. Time frame of the English Faecal Immunochemical Test (FIT) Pilot Study 2014, from pre-invitation period to the end of the
screening round.
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participants who provided a valid FIT sample; the latter
provides the dataset for analysis of the association between
pathology and f-Hb. This subpopulation was characterised
by relatively high proportions of non-deprived invitees
(more than 50% were in the two least deprived IMD quin-
tiles) and previous participants in CRC screening (75.1%).
Table 2 summarises categories of observed f-Hb by
demographic factors and screening episodes. The table
gives the numbers and proportions with undetectable f-
Hb, detectable f-Hb and positive f-Hb (f-Hb5 20 lg/g),
for the latter two subpopulations also giving the geometric
mean and empirical 80% ranges of f-Hb. Large propor-
tions of participants had undetectable f-Hb in all sub-
groups. There were significantly lower proportions with
undetectable f-Hb (i.e. higher proportions with some evi-
dence of bleeding) in the Midlands and North Western
Hub participants, in males, in older participants, in more
deprived populations, and in previous non-responders
(P< 0.001 in all cases).
Among positive cases, the overall geometric mean f-Hb
was 78 lg/g, compared with 18 lg/g for participants with a
detectable f-Hb. In the whole study population, FIT
results varied by screening hubs, sex, age groups and dep-
rivation index. Average f-Hb was similar between partic-
ipants in the Midlands and North West Hub and those in
the Southern Hub, although the latter hub had a higher
proportion with undetectable f-Hb. Male participants,
older participants and more deprived participants all had
a higher geometric mean f-Hb. The age effect was largely
due to lower numbers with undetectable f-Hb in the oldest
age group. Although previous non-responders had a
higher geometric mean f-Hb than either first-time invitees
or previous responders, this was not statistically significant
(although the previous non-respondents had a significantly
lower proportion of undetectable f-Hb).
For those with f-Hb of at least 20 lg/g, geometric means
were similar in all strata, with the exception of sex: males
had a much higher geometric mean f-Hb in both the whole
population and among the positive cases only. This sug-
gests that most of the other demographic differences are
predominantly driven by the proportions of undetectable
f-Hb. However, although in this group as a whole there
was no clear trend in f-Hb with age, there was a greater
tendency for older subjects with no CRC or adenoma to
have f-Hb of 20 lg/g or more: the proportions were 2.8%,
3.1% and 3.3% for age groups 59–64, 65–69 and 70–
75 years, respectively (p¼ 0.045).
Understanding the relationship between FIT-detected f-
Hb and pathology
As noted in the Methods section, the truncated regression
was carried out on the 1825 complete cases. The final mul-
tiple regression model (supplied in table S1) adjusted for
age and sex suggests that participants with CRC and HRA
had significantly higher f-Hb (p< 0.001). After controlling
for age and sex, participants who had CRC and HRA,
respectively, had log(f-Hb) approximately 3.08 higher
and 1.53 higher than those with no abnormality. Back-
transforming to the original scale, a participant with
CRC was estimated to have f-Hb 22 times that of a par-
ticipant of the same age and sex but with no abnormal
pathology (on average). After adjusting for age and sex,
the f-Hb of participants who had LRA or other abnormal-
ity were not statistically significant different from partic-
ipants who had no abnormality pathology (Wald tests,
p¼ 0.855 and p¼ 0.791).
Table 3 gives the empirical geometric mean, and 10th to
90th percentile ranges (referred to below as 80% ranges) of
f-Hb for each pathology and the corresponding estimated
80% ranges of the distribution of f-Hb, calculated from
the univariable truncated regression models. We calculated
80% ranges rather than 95% ranges (used in laboratory
quality control), as the latter were so wide as to be unin-
formative as to the concentrations characterising the cen-
tral bulk of the population. If the model is a good fit, we
expect 80% of cases to have observed f-Hb within the 80%
range estimated from the distribution. We note that whilst
the average f-Hb (geometric means) is strongly associated
with pathology, the 80% ranges are very wide, particularly
for CRC and HRA. To illustrate the overlap, Figure 2
shows the estimated distributions of f-Hb by pathology
on the same graph. There is a reasonable separation





N % N %
Hub
Southern 21,640 52.9 14,743 54.1
Midlands and North West 19,288 47.1 12,495 45.9
Sex
Female 21,064 51.5 14,404 52.9
Male 19,864 48.5 12,834 47.1
Age group in years
59–64 17,428 42.6 11,154 41.0
65–69 14,037 34.3 9685 35.6
70–75 9463 23.1 6399 23.5
IMD quintile
IMD 1 (most deprived) 5775 14.1 3016 11.1
IMD 2 6560 16.0 4081 15.0
IMD 3 8676 21.2 5883 21.6
IMD 4 9554 23.3 6686 24.6
IMD 5 (least deprived) 10,357 25.3 7568 27.8
IMD n/ka 6 0.01 4 0.01
Screening episode
Previous responders 22,737 55.6 20,465 75.1
First-time invitees 6453 15.8 3962 14.6
Previous non-responders 11,738 28.7 2811 10.3
Overall 40,928 100.0 27,238 66.6
Note: IMD 1 to IMD 5 is the scale from the most deprived to the least
deprived. FIT: Faecal immunochemical test; IMD: index of multiple
deprivation.
aParticipants where postcode could not be linked to layer super output areas
(LSOA).
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between CRC and no abnormality and other abnormality,
and a rather poorer separation of adenoma pathology
from no abnormality and other abnormality.
Figure 3 shows the estimated distribution of f-Hb
within each pathology with histograms corresponding to
observed f-Hb that are equal to or above 20 lg/g. Average
f-Hb is very low for most categories, with a high degree of
variation. For example, CRC having a mean and SD of
4.74 and 1.92, respectively, on the logarithmic scale
corresponds to an 80% range in the linear scale of
around 10–1339 lg/g.
Using regression results to estimate sensitivity of the
programme to different bowel pathologies
Using the univariable truncated regression results, Table 4
shows the estimated sensitivity of FIT to CRC and HRA,
and the percentage of participants who would be recalled
Table 2. Frequencies (proportions) of participants with undetectable f-Hb, and frequencies (proportions), geometric means and 80%
empirical ranges for participants with detectable and positive f-Hb (mg/g), stratified by demographic characteristics and screening episodes.
Undetectable f-Hba (<4 mg/g) Detectable f-Hba (54mg/g) Positive f-Hb (520mg/g)
N % N % Meanb 80% PRc N % Meanb 80% PRc
Hub
Southern 11,965 81.2 2778 18.8 19 5–126 1049 7.1 78 24–405
Midlands and North West 9468 75.8 3027 24.2 18 5–113 1084 8.7 78 25–389
Sex
Female 11,553 80.2 2851 19.8 16 5–90 947 6.6 69 24–300
Male 9880 77.0 2954 23.0 21 5–153 1186 9.2 86 25–481
Age group, years
59–64 9012 80.8 2142 19.2 18 5–120 771 6.9 78 25–389
65–69 7619 78.7 2066 21.3 18 5–120 747 7.7 80 25–383
70–75 4802 75.0 1597 25.0 19 5–113 615 9.6 76 24–401
IMD quintiled
IMD 1 (most deprived) 2199 72.9 817 27.1 20 5–123 324 10.7 75 24–359
IMD 2 3087 75.6 994 24.4 20 5–122 392 9.6 78 25–432
IMD 3 4657 79.2 1226 20.8 18 5–117 435 7.4 80 25–394
IMD 4 5314 79.5 1372 20.5 18 5–118 504 7.5 79 25–405
IMD 5 (least deprived) 6172 81.6 1396 18.4 17 5–111 478 6.3 78 24–416
IMD n/ke 4 . 0 . . . 0 . . .
Screening episode (n, %)
Previous responders 16,109 78.7 4356 21.3 18 5–111 1592 7.8 75 24–367
First-time invitees 3234 81.6 728 18.4 17 5–112 248 6.3 82 25–522
Previous non-responders 2090 74.4 721 25.6 22 5–175 293 10.4 91 25–450
Overall 21,433 78.7 5805 21.3 18 5–118 2,133 8 78 25–394
af-Hb, faecal haemoglobin concentration (mg/g).
bGeometric mean. c80% percentile range (PR) is the 10th and the 90th percentile observed.
dIMD, index of multiple deprivation. IMD 1 to IMD 5 is the scale from the most deprived to the least deprived.
eParticipants whose postcode could not be linked to lower layer super output areas (LSOA).
Table 3. Summary of faecal haemoglobin concentration (f-Hb) by pathology, with counts and corresponding proportion in colonoscopy;
geometric mean and 80% empirical percentile ranges, and 80% normal ranges estimated by truncated regression on 1825 complete cases.
N % of colonoscopya
f-Hb (lg/g)
Geometric Mean 80% rangeb 80% estimated rangec
Colorectal cancer 74 4.1 115 38–2178 10–1339
High-risk adenoma 216 11.8 38 26–723 4–356
Intermediate-risk adenoma 261 14.3 33 28–419 4–252
Low-risk adenoma 470 25.8 8 25–221 1–84
Other abnormality 538 29.5 0 24–312 0–1
No abnormality 266 14.6 0 24–271 0–6
80% range¼ geometric mean 1.1.28standard deviation.
aParticipants with colorectal cancer as a proportion of those underwent colonoscopy. For example, 4.1%¼ 74/1825.
b80% range is the 10th and the 90th percentile observed.
c80% estimated range are estimations from univariable truncated regression using ln(f-Hb) as the dependent variable.
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Figure 2. Distribution of f-Hb estimated by truncated regression with pathology on 1825 complete cases.
Figure 3. Distributions of observed f-Hb on the log scale for f-Hb at least 20lg/g and estimated FIT distributions from truncated regression
models, for each pathology, with mean, standard deviation and estimated percentage observed. There were 1825 complete cases only.
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for a number of thresholds. For example, a low threshold
such as 20 mg/g results in high sensitivity for detection of
CRC and moderate sensitivity for HRA, but would
require almost 7.8% of participants to undergo colonos-
copy. Note that specificity cannot be calculated since neg-
ative FIT did not result in further investigation.
Table 5 shows estimated prevalence in different inter-
vals, with sensitivities estimated from the model.
Consequently, these differ from those presented in
Table 4, which were based on observed frequencies.
However, the differences are very small, indicating that
the model fits rather well to the CRC and HRA data
(a more detailed comparison between estimated and
observed frequencies is presented in Table S2). The table
also gives the sensitivity of the lower point of each interval
as a threshold for further investigation. That is, a thresh-
old of 20 lg/g would confer 82.2% sensitivity to CRC and
64.0% sensitivity to HRA. The table indicates that the
current threshold of 120 lg/g has a poor sensitivity for
both CRC and HRA, only correctly identifying 48.9%
and 25.6%, respectively (Table 5). Further, a very low
FIT threshold (40 lg/g) is required in order to detect
71.1% of CRC and 48.2% of HRA (Table 5). The table
also shows, for example, that for participants with f-Hb of
80–119 lg/g, 35.4 per 1000 (just under 4%) have CRC
(more estimations on prevalence and sensitivity for all
abnormalities by f-Hb are given in Tables S3–S5).
Discussion
We analysed data from 27,238 FIT participants, and car-
ried out truncated regression on the 1825 (complete cases)
participants who underwent colonoscopy as a result of a
FIT result (f-Hb) of 20 lg/g and above. We estimated the
influence of demographic factors and colonoscopy find-
ings on f-Hb, and calculated the expected results of differ-
ent f-Hb thresholds in terms of both detected and missed
CRC and adenomas.
The higher proportion with detectable levels in older
participants is consistent with the results of Clark et al.10
In our data, the mean concentration among participants
with positive results was relatively stable over age. This
suggests that older participants have a greater tendency to
bleeding and we might speculate that they do so regardless
of presence or not of significant bowel abnormalities. Clark
et al. suggest that this tendency may be a marker of systemic
inflammation.10 Others have found that older participants
have more false positive FIT results at the low threshold of
17lg/g.11 In our data, with a threshold of 20lg/g, there is
also some evidence of this, with proportions of complete
cases having no CRC or adenoma but with f-Hb of 20lg/
g or more being 2.8%, 3.1% and 3.3% for age groups
59–64, 65–69 and 70–75 years respectively (p¼ 0.045).
In contrast, amongst those with positive FIT results,
males had a much higher geometric mean than females,
and a much higher limit of the 80% range. Higher concen-
trations in males were also noted by Clark et al.9 and by
Ribbing et al.12 Thus, the difference between males and
females is driven in large measure by higher f-Hb of bleed-
ing in those with positive f-Hb.
Since definitive pathology was only available for posi-
tive participants (f-Hb 520 mg/g), we used truncated
regression methods to estimate the influence of bowel
pathology on f-Hb and the sensitivity of different thresh-
olds to CRC and HRA.
Using data from 1825 complete cases, we found that
participants with CRC and HRA have considerably
increased f-Hb, but that the variation among patients is
very large. This has been observed by others.13 Despite
distinguishing upper bounds in f-Hb amongst pathology
of different risks, the large overlap at intermediate and low
f-Hb imposes challenges under current dichotomised
screening policies, in which participants in England with
f-Hb at or above a single threshold (120 mg/g) are referred
for colonoscopy and participants below that concentration
receive their next screen two years later.
Table 4. Sensitivities to CRC and HRA by f-Hb thresholds and observed numbers and proportions above these thresholds.
Sensitivity for pathology (number and percentage) above threshold
CRC HRA No/other abnormalitya All participants
Threshold (lg/g) Number % Number % Number % Number %
4 (86) 95.6 (303) 90.2 (4051) 16.5 5805 21.3
10 (81) 90.0 (261) 77.7 (2071) 8.4 3423 12.6
20 74 82.2 216 64.3 1112 4.5 2133 7.8
40 66 73.3 168 50.0 703 2.9 1421 5.2
80b 53 58.9 108 32.1 375 1.5 802 2.9
120b 43 47.8 84 25.0 269 1.1 576 2.1
150b 40 44.4 70 20.8 228 0.9 483 1.8
180 36 40.0 59 17.6 195 0.8 411 1.5
Note: Numbers for thresholds 4 and 10 (in brackets) are estimated from univariable truncated regression model on 1825 complete cases. All others observed
from all 27,238 participants in the pilot study.
a‘No/other abnormality’ are calculated by subtraction from observed totals.
b80, 120 and 150lg/g are thresholds chosen for the national programmes in Scotland, England and Wales, so included here.
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Our regression results indicate that the f-Hb threshold
of 120 lg/g used in the NHS BCSP in England is likely to
miss just over half of the CRC (51.1%) present at the time
of sampling (Table 5). Ribbing et al. found considerably
lower sensitivity at various thresholds for CRC and
advanced adenoma (not the same as HRA; please refer
to the paper for a precise definition) combined.12 In sub-
jects with f-Hb of 80–119lg/g, which would not trigger
further investigation in the current programme in
England, just under 4% had CRC (Table 5). This is
higher than the 3% risk threshold for a two-week wait
referral for suspected cancer in symptomatic subjects. To
capture 80% of CRC and around 60% of HRA, a thresh-
old of 22 lg/g is indicated by our results (Tables 4, 5 and
S5). This is consistent with Whyte et al., who concluded
that, in the absence of colonoscopy capacity issues, the
most cost-effective FIT strategy would be a threshold of
20 lg/g.14 However, this would imply referring 7.5% of
participants for colonoscopy (Table S5). Even prior to
the COVID-19 crisis, colonoscopy capacity in England
could not cope with this, and the capacity is likely to be
even lower for the foreseeable future. Therefore, to main-
tain acceptable sensitivity to CRC and HRA, one might
consider using the quantitative f-Hb more fully,15 with
different actions for different f-Hb categories, for example:
• Undetectable f-Hb: delay next screen to three years;16
• Very low f-Hb: next screen in two years;17
• Low f-Hb: repeat screening test in three months to
assess persistence of bleeding;18
• Medium f-Hb: flexible sigmoidoscopy to examine the
lower part of the colon (distal), and remove any abnor-
malities found, followed by a further FIT to ascertain
whether the cause of the bleeding has been removed;19
• High f-Hb: colonoscopy.
Note that we are not explicitly recommending exactly
this strategy or these actions. This is simply an example of
the approach one might take. More data is needed to
ascertain the safety and effectiveness of such an approach,
and to specify thresholds for different actions. Others have
proposed varying strategies of f-Hb threshold and inter-
screening interval. For example, Haug et al. suggested a
low threshold at first screen and a long interval to
second.20 However, Digby et al. estimated that this
would lead to non-negligible numbers of cases missed,
and suggested as an alternative an interval determined
on the basis of concentration at the first screen.14
Further research using this and other datasets will indicate
the likely thresholds to define the above categories.
When truncated regression removes a majority of the
data, estimates are less reliable.9,21 Thus, those with a ‘no
abnormality’ or ‘other abnormality’ pathology would be
overwhelmingly below the threshold of 20 lg/g, and there-
fore estimates for these would be less reliable. This is a
limitation of the present study, and renders estimation of
false positive results (no abnormality pathology with f-Hb
above the threshold) uncertain. Estimation of false posi-
tive and false negative rates for thresholds below 20 lg/g
remains a target for the future.
It should also be noted that the absolute f-Hb results
reported here pertain specifically to the OC-Sensor
DIANA analyser. While the observations of associations
of demographic variables and pathology with concentra-
tions are likely to be generalisable, exact numbers will not
be.
Another limitation is that models fitted did not control
for factors such as villous status and location of adeno-
mas, which are known to influence f-Hb.13,22 These factors
are also associated with risk of future CRC. Taking
account of these is another target for the future.
Conclusion
This analysis shows that the current threshold of 120 lg/g
in the English NHS BCSP may only correctly identify half
Table 5. Estimated prevalence of CRC and adenomas per 1000 participants and sensitivity to CRC and HRA by f-Hb categories; estimates
derived from the regression results.
Prevalence per 1000 participants Sensitivity at a given threshold
f-Hb category CRC HRA IRA LRA HRAþ CRC HRA HRAþ
<4 0.2 1.5 1.7 25.9 1.7 100.0% 100.0% 100.0%
4–9 2.1 17.6 23.5 125.5 19.7 95.6% 90.2% 91.3%
10–19 5.4 34.9 48.1 168.2 40.3 90.0% 77.7% 80.3%
20–39 14.0 73.0 101.1 252.8 87.1 82.2% 64.0% 68.1%
40–79 19.4 84.0 111.5 210.0 103.4 71.1% 48.2% 53.5%
80–119 35.4 115.0 146.0 230.1 150.4 57.8% 33.3% 38.5%
120–149 43.0 150.5 172.0 247.3 193.5 48.9% 25.6% 30.5%
150–179 41.7 125.0 166.7 222.2 166.7 44.4% 21.4% 26.3%
180þ 90.0 153.3 143.6 167.9 243.3 41.1% 18.8% 23.5%
Note: Sensitivity estimated of the lower point of each interval as a threshold for further investigation. HRAþ are colorectal cancers and high-risk adenomas
combined.
f-Hb: Faecal haemoglobin concentration (lg/g). CRC: colorectal cancer; HRA, IRA and LRA: high-, intermediate- and low-risk adenomas.
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of CRC and a quarter of all HRA in the population. In
order to achieve better detection rates of bowel abnormal-
ities, while minimising the burden on endoscopy resources,
the NHS BCSP might make use of the ability of FIT to
provide quantitative results to develop a multi-threshold
management strategy, thereby optimising clinical resour-
ces and patient outcomes.
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